1. Home
  2. STC vs ZYME Comparison

STC vs ZYME Comparison

Compare STC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stewart Information Services Corporation

STC

Stewart Information Services Corporation

HOLD

Current Price

$71.90

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.75

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STC
ZYME
Founded
1893
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
STC
ZYME
Price
$71.90
$26.75
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$81.50
$30.67
AVG Volume (30 Days)
260.5K
740.0K
Earning Date
02-04-2026
11-06-2025
Dividend Yield
2.93%
N/A
EPS Growth
69.60
N/A
EPS
3.60
N/A
Revenue
$2,796,513,000.00
$134,481,000.00
Revenue This Year
$17.67
$63.57
Revenue Next Year
$10.14
$89.45
P/E Ratio
$19.95
N/A
Revenue Growth
16.09
116.21
52 Week Low
$56.39
$9.03
52 Week High
$78.61
$28.49

Technical Indicators

Market Signals
Indicator
STC
ZYME
Relative Strength Index (RSI) 45.24 61.80
Support Level $70.90 $25.94
Resistance Level $73.66 $27.94
Average True Range (ATR) 2.37 1.08
MACD -0.42 -0.15
Stochastic Oscillator 23.28 65.71

Price Performance

Historical Comparison
STC
ZYME

About STC Stewart Information Services Corporation

Stewart Information Services Corp is a customer-focused, title insurance and real estate services company offering products and services to home buyers and sellers, mortgage lenders and servicers, attorneys, and home builders. It has three operating segments; Title insurance and related services which generates key revenue, includes the functions of searching, examining, closing, and insuring the condition of the title to real property. It also includes home and personal insurance services, Real estate solutions segment supports the real estate mortgage industry by providing appraisal management services, online notarization and closing solutions, credit, and real estate information services, search and valuation services. Corporate and other segment is comprised of parent holding company.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: